ArticleBiology direct2025
Platelet-activating factor induces ferroptosis by binding to ATF3 and inhibiting the SLC7A11/GPX4 axis to suppress the progression of endometrial carcinoma.
Article in Biology direct, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundEndometrial carcinoma (EC) is an aggressive gynecological malignancy with high recurrence rates and limited treatment options. Patients with EC exhibit elevated serum levels of lyso-platelet-activating factor (lyso-PAF), a biologically inactive product generated during the hydrolysis of PAF by PAF-acetylhydrolase (II) (PAF-AH2). Nevertheless, the biological function of PAF in EC progression and the relationship between abnormal lyso-PAF levels and EC progression remain unclear.
resultsIn this study, we identified the bioactive phospholipid mediator–PAF, which effectively suppress tumor growth both in vitro and in patient-derived organoid models. By combining the cellular thermal shift assay, drug affinity responsive target stability approach, molecular docking simulation, and surface plasmon resonance analysis, we identified activating transcription factor 3 (ATF3) as the direct binding target of PAF with a Kd of 3 0.24 µM. Mechanistically, PAF enhanced ATF3 stability through deubiquitination. In addition, ATF3 knockdown partially reversed the effects of PAF-induced SLC7A11 and GPX4 transcriptional inhibition. In vivo studies using a nude mouse xenograft model confirmed the ferroptosis-mediated tumor-suppressive effects of PAF, as evidenced by hematoxylin and eosin staining and immunohistochemical analysis. Clinically, proteomic analysis revealed upregulation of PAF-AH2 expression in EC tissues derived from patients. Subsequent analysis of EC tissue microarrays revealed that high PAF-AH2 expression is associated with poor survival.
conclusionsIn conclusion, this study demonstrates that PAF inhibits EC tumor growth by inducing ferroptosis and that the underlying mechanisms of its action involve the targeting of ATF3. These findings suggest that PAF metabolism may be a promising direction for EC diagnostics and therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.